DRUG DISCOVERY SERVICES PROVIDED THROUGH

Brand Owner Address Description
FLUENCY Immuneering Corporation 245 Main Street, Second Floor Cambridge MA 02142 drug discovery services provided through a computer software platform used for research and development in the field of drugs; pharmaceutical research and development; providing medical research and scientific information in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; providing medical and scientific research information in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials via the internet; research and development of new products; medical and scientific research in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; platform as a service (PAAS) or software as a service (SAAS) featuring computer software platforms using biology and chemistry analytics for determining drug candidates with reduced toxicity; platform as a service (PAAS) or software as a service (SAAS) featuring computer software platforms for database mining, database analysis, database management and the application of artificial intelligence; consultancy in relation to the development and implementation of software and software based applications; drug discovery services using artificial intelligence to predict, identify, and rank drug candidates; artificial intelligence-assisted automated drug discovery services to predict, identify and rank the binding potential of chemical compounds to a target protein;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. A crystal comprising LuxP is obtained, and a binding site for autoinducer-2 (AI-2) identified. The X-ray crystallographic data for LuxP and a LuxP-AI-2 complex is determined and used in a drug discovery method. Pharmaceutical compositions comprising ligands identified by such drug discovery methods are used to treat bacterial infections.